Uy Ear
Stock Analyst at Mizuho
(2.97)
# 1,494
Out of 4,918 analysts
63
Total ratings
42.11%
Success rate
12.27%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $40 → $14 | $15.91 | -12.01% | 8 | Jul 21, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $20 → $23 | $23.53 | -2.25% | 11 | May 19, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $20.73 | +310.03% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $14.29 | +46.96% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $13.70 | +46.04% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.59 | +69.43% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $26.55 | +50.66% | 5 | Nov 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $12.38 | +223.10% | 1 | May 24, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $9.15 | +151.37% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $128.91 | +8.60% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $167.33 | -76.10% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.44 | +594.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.99 | +201.93% | 2 | Mar 1, 2023 |
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Neutral
Price Target: $40 → $14
Current: $15.91
Upside: -12.01%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $23.53
Upside: -2.25%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $20.73
Upside: +310.03%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $14.29
Upside: +46.96%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $13.70
Upside: +46.04%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.59
Upside: +69.43%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $26.55
Upside: +50.66%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $12.38
Upside: +223.10%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $9.15
Upside: +151.37%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $128.91
Upside: +8.60%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $167.33
Upside: -76.10%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.99
Upside: +201.93%